Sutro Biopharma to Participate in Upcoming Investor Conferences

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in several upcoming investor conferences.

Conference Details:

TD Cowen 46th Annual Health Care Conference Date: March 2-4, 2026 Location: Boston, MA

Leerink Partners Global Healthcare Conference Date: March 8-11, 2026 Location: Miami, FL

The Citizens Life Sciences Conference Date: March 10-11, 2026 Location: Miami, FL

Barclays 28th Annual Global Healthcare Conference Date: March 10-12, 2026 Location: Miami, FL

Webcasts of the fireside chats at the TD Cowen and Citizens conferences will be accessible through the Events & Presentations page of the Investor Relations section of the Company’s website at www.sutrobio.com . Archived replays will be available for at least 30 days after the event.

About Sutro Biopharma Sutro Biopharma, Inc. is advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what’s possible in cancer therapy. The Company’s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies. For more information, follow Sutro on social media @Sutrobio or visit www.sutrobio.com .

Investor Contact Emily White Sutro Biopharma (650) 823-7681 [email protected]

Media Contact Amy Bonanno Lyra Strategic Advisory [email protected]